Monthly Archives: September 2011

STOCKHOLM (MedPage Today) — Adding the PARP inhibitor iniparib to gemcitabine (Gemzar) plus carboplatin (Paraplatin) may benefit triple-negative metastatic breast cancer patients when used as second- or third-line therapy, researchers said here.

STOCKHOLM (MedPage Today) — Patients who’ve undergone treatment for metastatic colorectal cancer had “statistically significant and clinically meaningful” improvement in survival when also given a multitargeted angiogenesis inhibitor, investigators reported here.

STOCKHOLM (MedPage Today) — The risk of skeletal-related events declined significantly in patients with advanced cancer who were treated with denosumab rather than zoledronic acid, pooled data from three large trials showed.

STOCKHOLM (MedPage Today) — Complication rates — and costs — tied to chemotherapy in metastatic breast cancer are not mitigated by the addition of anti-HER2 therapy, researchers said here.

STOCKHOLM (MedPage Today) — For women with recurrent ovarian cancer who are being treated with trabectedin, outcomes do not appear to be affected by the abnormal liver enzymes associated with the drug, researchers found.

STOCKHOLM (MedPage Today) — Treatment of recurrent ovarian cancer with bevacizumab (Avastin) in a “real world” setting appears to safely produce results observed in clinical trials, researchers said here.

STOCKHOLM (MedPage Today) — Bevacizumab (Avastin) remains effective in prolonging progression-free survival in patients with recurrent ovarian cancer, regardless of their platinum-sensitivity status, researchers said here.

STOCKHOLM (MedPage Today) — Russian researchers suggested here that a molecular analysis of plasma cells from patients with multiple myeloma might give clues about when targeted therapies would be most appropriate.

STOCKHOLM (MedPage Today) — Adding sorafenib (Nexavar) to standard chemotherapy or hormone therapy for metastatic breast cancer patients won’t extend progression-free survival, researchers said here.

STOCKHOLM (MedPage Today) — Vorinostat (Zolinza) failed to extend survival as a second-line therapy in patients with malignant pleural mesothelioma, researchers said here.